Rheumatoid Arthritis News

The FDA has issued a safety alert warning patients and health providers of an increased risk for serious health-related problems and cancer linked to tofacitinib compared with TNF inhibitors among older patients.

Patients with rheumatoid arthritis, particularly older women, who are overweight demonstrate less joint space narrowing progression, independent of smoking status, according to data published in Arthritis Research & Therapy.

A greater percentage of patients with psoriatic arthritis achieve remission with biologic therapy than those with rheumatoid arthritis, at both 1- and 12-year follow-up, according to data published in Arthritis Research & Therapy.

Patients with rheumatoid arthritis who receive abatacept demonstrate similarly low rates of opportunistic infections as those treated with a placebo, according to data published in Arthritis Research & Therapy.

Undeterred by the FDA’s rejection of filgotinib over testicular toxicity concerns, the United Kingdom’s National Institute for Health and Clinical Excellence has endorsed its use among eligible patients on England’s National Health Service.

Cardiovascular disease incidence among women and patients younger than 55 years with rheumatoid arthritis is higher than their typical “low risk” classification would suggest, according to data published in Arthritis Research & Therapy.

If there was any question about whether rheumatologists would utilize an effective biomarker that can predict response to a commonly used class of drugs, it was answered by a recent study in Rheumatology International.

Higher disease activity and levels of cytokines or chemokines are associated with an increased risk for diabetes mellitus in patients with rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.

The adjusted multibiomarker disease activity test for rheumatoid arthritis is prognostic for radio progression, and is a stronger predictor than conventional risk factors, according to data published in Arthritis Research & Therapy.

Patients being treated with tumor necrosis factor inhibitors or methotrexate who acquired COVID-19 did not experience elevated hospitalization or mortality rates, according to a study.